Skip to content
Medical Health Aged Care

Engineer-mum turns breastmilk worries into smart device for parents

Monash University 3 mins read
  • Monash University engineers have developed a world-first, device that accurately tracks how much breastmilk a baby drinks - in real time.

  • Perceived insufficient milk supply (PIMS) is one of the leading reasons women stop breastfeeding before six months, despite meeting their baby’s needs.

  • Inspired by her own experience as a new mum, Dr Fae Marzbanrad created the AI-powered monitor - now close to commercialisation.

For countless new mums, one of the hardest parts of breastfeeding isn’t the latch or the logistics - it’s the uncertainty. Is my baby getting enough? Am I making enough? 

Perceived insufficient milk supply (PIMS) is a major reason why women stop breastfeeding before the minimum six months recommended by Australian guidelines.

A large review, published in 2021, found that – amongst breastfeeding mothers – perceived insufficient milk supply (PIMS) is one of the major reasons for discontinued breastfeeding, with approximately 50 per cent of mothers reported PIMS as the reason for stopping breastfeeding.

Now a Monash University researcher has developed a smart device that measures, in real time, how much milk a baby consumes while breastfeeding.

The device, developed by Dr Fae Marzbanrad and her team at the Faculty of Engineering, works by placing a small probe on the baby’s neck while feeding. . A working wireless prototype has been developed and is now close to commercialisation.

The sensor records signals that use AI to instantly measure the amount of milk the baby consumes per feed. 

“My baby wasn’t putting on enough weight, which was a stressful and difficult experience as an overwhelmed new mum,” said Dr Marzbanrad, head of the Biomedical Signal Processing Research Lab at Monash.

“I also found that this was a common experience for other women in my mother’s group. So, I developed a device to solve this problem, and many mums I know are now waiting for it and willing to pay for it.”

In a new pilot study of 24 newborns, the Infafeed monitor successfully showed that it can track newborn feeding accurately, addressing a longstanding gap in neonatal feeding assessment with a non-invasive, AI-powered solution.

“Maternal concern about insufficient milk supply is a major cause of premature cessation of exclusive breastfeeding. The Infafeed monitor provides a non-invasive objective tool for assessing neonatal milk intake, with the potential to reduce unnecessary supplementation, enable early identification of feeding problems, and support breastfeeding continuation,” Dr Marzbanrad said.

The monitor was developed in collaboration with Associate Professor Atul Malhotra, a neonatologist from Monash Department of Paediatrics and Monash Children's Hospital. The researchers believe that, if validated in larger studies, the monitor could enhance breastfeeding support strategies in both clinical and home settings.

“The technology could be particularly beneficial for preterm or low birth weight babies when they transition from gastric tube feeding to breast or bottle feeding, helping them gain weight more effectively while providing parents with accurate data and peace of mind,” Associate Professor Malhotra said.

The work has already generated significant interest among parents and medical professionals eager for a reliable, non-invasive solution to monitor infant feeding.

DOI: 10.5005/jp-journals-11002-0121

MEDIA ENQUIRIES:

Courtney Karayannis, Media and Communications Manager

Monash University

T: +61 408 508 454 or [email protected] 


GENERAL MEDIA ENQUIRIES

Monash Media

P: +61 3 9903 4840

E: [email protected]

For more experts, news, opinion and analysis, visit Monash News.

Media

More from this category

  • Business Company News, Medical Health Aged Care
  • 13/11/2026
  • 12:58
VNDentalTravel

VNDentalTravel Highlights Between-Visit Planning for Australians Seeking Dental Implants

Key Facts: VNDentalTravel is advising Australian patients that dental implant treatment in Vietnam typically spans two visits, with implant placement occurring in the first visit and the final crown fitted at a later stage following a healing interval.Patients are encouraged to plan leave, budget for a return journey, and understand what treatment remains outstanding before travelling home to Australia.During the interval in Australia, patients should obtain written aftercare instructions, implant details, and contact information for their Vietnamese dental team, and arrange any necessary local dental reviews independently.Travel arrangements, including accommodation, transport, and any tourism activities, should be planned around appointment…

  • Biotechnology, Medical Health Aged Care
  • 13/11/2026
  • 09:20
Aravax

Aravax Announces Positive Results of Phase 2 Clinical Trial of PVX108, a Novel Immunotherapy for the Treatment of Peanut Allergy

Melbourne, Australia, 13 November 2026— Aravax, a clinical‑stage biotechnology company developing next‑generation therapies for food allergy, today announces positive topline results in children from its Phase 2 clinical trial involving its lead product, PVX108 for the treatment of peanut allergy. PVX108 is an investigational, next-generation immunotherapy which uses proprietary peptides designed to precisely retrain the immune system to tolerate peanut whilst minimising treatment-induced acute allergic reactions. It has been awarded FDA Fast Track designation for the treatment of peanut allergy. Dr Pascal Hickey, CEO, Aravax said, “PVX108 is the first therapy designed to precisely target the root cause of peanut…

  • Medical Health Aged Care
  • 13/11/2026
  • 06:51
Cyclarity Therapeutics

Cyclarity Therapeutics Receives FDA Investigational New Drug Clearance for UDP-003 to expand Atherosclerosis Clinical Development Program into the United States

NOVATO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cyclarity Therapeutics, Inc., a clinical-stage biotechnology company developing cyclodextrin therapeutics to reverse atherosclerotic cardiovascular diseases and metabolic diseases of aging, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for UDP-003. UDP-003, designed by Cyclarity’s proprietary AI-enabled computational platform, is engineered to bind and extract oxidized cholesterol to restore cellular function and spur atherosclerotic plaque regression.The IND clearance authorizes the expansion of Cyclarity Therapeutics’ Phase 1b trials to the United States, complementing the ongoing study in Australia. The study (NCT06813339; CTx-001) is a…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.